Pituitary tumor-transforming gene (pttg) is a distinct proto-oncogene which is expressed in certain normal tissues with high proliferation rate and in a variety of tumors. PTTG is the vertebrate analog of yeast securins Pds1 and Cut2 with a key role in the regulation of sister chromatid separation during mitosis. Impairment of PTTG regulated functions is expected to lead to chromosomal instability and aneuploidy. Human pttg (hpttg) is abundantly expressed in Jurkat T lymphoblastic lymphoma cells but not in normal peripheral blood leukocytes. To obtain additional data on the potential role of hpttg in lymphomagenesis we selected 150 cases of lymphoid tumors for the assessment of hpttg expression in tumor tissues. Immunohistochemical studies on formalin-fixed, paraffin-embedded tissues revealed hPTTG in 38.8% of B-cell lymphomas, 70.2% of Tcell lymphomas, and 73.1% of Hodgkin's lymphomas. Among B-cell lymphomas, the most frequently immunostained tumors were plasma cell tumors, diffuse large cell lymphomas, and follicle center cell lymphomas. In Hodgkin's disease, immunoreactivity was mainly noted in Reed-Sternberg cells. In conclusion, the frequent overexpression of hpttg in many histological subtypes of lymphoma suggests the involvement of this protooncogene in lymphomagenesis.
Pituitary tumor-transforming gene (pttg) was originally isolated from clonal rat GH4 pituitary tumor cells. This gene is diferentially expressed in tumorous but not in normal pituitary cells, and its overexpression in NIH3T3 mouse fibroblasts is able to induce cell transformation in vitro and tumor formation in vivo when transformed cells are injected into athymic mice (Pei and Melmed, 1997) . A human homolog of pttg, hpttg, was first cloned from a thymus cDNA library (Domı´nguez et al., 1998) . hpttg gene is expressed in pituitary adenomas as well as in other epithelial tumors such as breast, lung, and colorectal carcinomas (Sa´ez et al., 1999; Zhang et al., 1999a; Heaney et al., 2000) . We have demonstrated a correlation between hpttg expression and cell proliferation in vitro. hPTTG protein level is up-regulated in rapidly proliferating cells, is downregulated in response to serum starvation or cell confluence, and is regulated in a cell cycle-dependent manner peaking in mitosis (Ramos-Morales et al., 2000) . hpttg has been mapped to chromosome 5q33 (Zhang et al., 1999b) , a region that is associated with reports of neoplastic diseases, including myeloid leukemia, chronic myeloproliferative disorders, and myelodisplastic syndromes (Strausberg et al., 1997) .
hPTTG is a protein of 202 amino acids that has a basic N-terminal portion and an acidic C-terminal portion (Domı´nguez et al., 1998) . It has several putative SH3-binding sites (Domı´nguez et al., 1998) and a conserved motif localized in the N-terminal portion matches the destruction box (D-box) shared by many anaphase-promoting complex or cyclosome substrates (King et al., 1996) . Recently, hpttg gene product has been identified as a vertebrate securin, involved in the regulation of sister-chromatid separation during mitosis (Zou et al., 1999) . Defective separation could lead to chromosome missegregation and aneuploidy. On this basis, genomic imbalance as a result of chromosome missegregation provides an explanation for the oncogenic potential of dysregulated hpttg expression (Jallepalli et al., 2001) . Gain of oncogene dosage and loss of tumor supressor genes are increasingly being identified as frequent events in the lymphomatous process (Werner et al., 1997; Rao et al., 1998) . The fact that Jurkat lymphoblastic T cells express high levels of hpttg mRNA, in contrast to its undetectable expression in peripheral blood lymphocytes (Domı´nguez et al., 1998) , prompted us to assess the expression of hpttg in tissues affected by malignant lymphoproliferative disorders, both at the mRNA and protein levels. The availability of a policlonal antihPTTG antibody (Domı´nguez et al., 1998) that efficiently works in paraffin sections allowed us to determine the expression of hPTTG in a series of 150 lymphomas by immunohistochemistry. The specificity of this antibody has been previously demonstrated with the use of immunoabsorption controls (Sa´ez et al., 1999) .
All tumors were collected from the archives of the Department of Pathology, reviewed by two independent pathologists and classified according to the Revised European-American Lymphoma (REAL) classification (Harris et al., 1994) . Table 1 (Figure 1a -f) , plasma cell neoplasias (seven out of 10), follicular lymphomas (eight out of 18), and diffuse large cell lymphomas (six out of 14) were found to be the most frequent subtypes expressing detectable levels of hPTTG. Other B-cell malignancies analysed had either very weak or absent immunoreactivity for hPTTG in most cases. Only one out of six mantle cell lymphomas, two out of nine Burkitt's lymphomas, and two out of 10 MALT lymphomas had immunohistochemically detectable levels of hPTTG. None of the three small lymphocytic lymphomas were positive for hPTTG. Overall, T cell lymphomas were the most heavily immunostained with anti-hPTTG antibody. Positivity was very intense in 10 cases: one nasal angiocentric lymphoma, five peripheral T-cell lymphomas, three mycosis fungoides, and one case of anaplastic large cell lymphoma ( Figure  1g -j). In Hodgkin's lymphomas, Reed-Sternberg cells and variants were markedly labeled by anti-hPTTG antibody and became easily distinguished from the background of small lymphocytes that showed very low levels of hPTTG expression ( Figure 1k ). Expression of hpttg mRNA was also analysed in selected cases by in situ hybridization on cryostat tissue sections. Using a digoxigenin-labeled antisense hpttg riboprobe we demonstrated an intense hpttg mRNA signal in the cytoplasm of Reed-Sternberg cells ( Figure  1l ). Expression of hpttg mRNA was also confirmed in available cryostat sections from B-cell lymphomas of the follicular and diffuse large cell subtypes. In addition, expression of hpttg was analysed by Northern blot in 35 cases of the series with available frozen tissues. In Northern blots (Figure 2 ), detectable levels of hpttg mRNA were found in most cases studied (27 out of 35). Densitometric quantitation yielded variable hpttg mRNA to 18S RNA ratios within each group of lymphoma subtypes (e.g. 0.14 -1.06, mean 0.66 for follicular lymphomas; 0.73 -1.25, mean 0.86 for diffuse large B-cell lymphomas). Levels of hpttg mRNA correlated with the intensity of immunostaining in these cases, which suggests that upregulation of hpttg occurs at the transcriptional level. Expression of hpttg mRNA was not detected on blots in samples from normal lymph nodes, but was noted in one case of lymphoid hyperplasia. By immunohistochemistry hPTTG was observed in cells of the germinal centers in cases of lymphoid hyperplasia. Taken together, these data suggest that hpttg is involved in the neoplastic process of many histological subtypes of lymphomas. Genetic instability in most cancers is observed at the chromosome level and results in losses and gains of whole chromosomes leading to aneuplody. Alterations in genes involved in the processes of replication and segregation of chromosomes during mitosis can lead to chromosomal instability . In some cases this chromosomal instability is associated with alterations in the mitotic spindle checkpoint In situ hybridization of hpttg mRNA in Hodgkin's lymphoma. Antisense hpttg digoxigenin (DIG)-labeled riboprobe was obtained by in vitro transcription (Roche Molecular Biochemicals, Mannheim, Germany) using a plasmid containing 700 bp hpttg cDNA sequence as template. Five-mm-thick cryostat sections were fixed in 4% paraformaldehyde in DEPC-treated PBS for 30 min. Hybridization and posthybridization conditions were those recommended by manufacturer's protocols. Anti-DIG antibody coupled to alkaline phosphatase and NBT/BCIP were used for signal detection (Roche Molecular Biochemicals). Nuclear fast red was the counterstain. Sections hybridized under the same experimental conditions but with sense hpttg riboprobe were used as negative controls. Bars, 50 mm hpttg expression in lymphomas C Sáez et al (Cahill et al., 1998) , which controls the proper bipolar segregation of duplicated sister chromatids before anaphase (Hardwick, 1998) . PTTG regulated degradation appears to be essential for the separation of sister chromatids and mitotic exit. Recently, it has been demonstrated that PTTG is needed for maintaining chromosomal stability in humans. The inactivation of hpttg in a karyotypically stable colorectal cancer cell line via homologous recombination led to retardation of chromosome separation and hpttg-deficient cells exhibited high chromosome loss rates (Jallepalli et al., 2001) . DNA damage-induced cell cycle checkpoints are also control mechanisms that prevent cells with DNA damage from entering mitosis. Alterations in genes involved in the pathways of these checkpoints have been also implicated in tumorigenesis (Dasika et al., 1999) . In Saccharomyces cerevisiae, the DNA damage that elicits a mitotic checkpoint arrest induces the phosphorylation of Pds1 protein (Cohen-Fix and Koshland, 1997), the budding yeast homolog of hPTTG. We have recently reported that hPTTG interacts with the DNA-dependent protein kinase (DNA-PK) (Romero et al., 2001 ), a heterotrimeric enzyme complex involved in the repair of DNA double-strand breaks (Jin and Weaver, 1997) . hPTTG specifically interacts with the Ku-70 subunit, and forms a complex with the Ku-70/Ku-80 heterodimer in intact cells. In addition, hPTTG is phosphorylated in vitro by the DNA-PK catalytic subunit. This association of hPTTG with the Ku-70/Ku-80 heterodimer is prevented by the presence of DNA double-strand breaks indicating that the induction of DNA damageresponse pathways might be connected with sister chromatid separation, in the way that inhibition of hPTTG-Ku interaction might favor the delay of the onset of mitosis while DNA repair takes place. Mice deficient in Ku-70 develop spontaneous thymic and disseminated T-cell lymphomas with multiple karyotypic abnormalities (Li et al., 1998) . It cannot be ruled out the possibility that both inactivation of ku-70 gene and defective regulation of PTTG leading to alterations in sister chromatid exchange and separation cooperate to facilitate lymphomagenesis.
There are several lines of evidence that PTTG might also function in vivo as a transcriptional activator. The C-terminal region of hPTTG is able to transactivate when fused to a heterologous DNA-binding domain (Domı´nguez et al., 1998) . Also, cotransfection experiments with PTTG and PBF (PTTG binding factor) led to the transcriptional activation of the basic fibroblast growth factor promoter (Chien and Pei, 2000) . Most interestingly, it has recently been reported that PTTG binds to c-myc promoter and activates cmyc transcription in transfected cells (Pei, 2001) . The c-myc proto-oncogene product is a critical regulator of cell proliferation and its expression is frequently altered in human tumors (Marcu et al., 1992) . Dysregulation of c-myc expression is a well known molecular event in most cases of Burkitt's lymphoma, mouse plasmacytoma, as well as many large B cell lymphomas harboring translocation t(8;14) that juxtaposes the c-myc gene and an immunoglobulin locus (Cory, 1986; Landanyi et al., 1991; Rabbits, 1994) . In Burkitt's lymphoma, mutations may either abrogate the negative regulation of c-myc transcription or increase the stability of the c-Myc protein leading to increased c-Myc protein activity (Hecht and Aster, 2000) . Also, c-Myc seems to play a role in the genesis of T cell lymphomas since c-myc gene is disrupted and dysregulated in T cell tumors of v-myb infected transgenic mice (Davies et al., 1999) . The identification of PTTG as a transcriptional activator of c-myc may provide a new mechanism that contributes to the dysregulation of c-myc expression in lymphomas with elevated levels of PTTG.
The identification of tumors that overexpress hpttg could be of potential use in the clinical setting since hpttg mRNA levels have been related to invasiveness in colorectal tumors (Heaney et al., 2000) . Cell cycledependent expression of hpttg (Ramos-Morales et al., 2000) could suggest a correlation between the state of proliferation and the expression of hpttg in tumors, but certain slowly proliferating tumors (e.g. pituitary adenomas) do express very high levels of hpttg. In our cases of follicular lymphomas and diffuse large Bcell lymphomas, that averaged low and high proliferation indices respectively, correlation between proliferation and hPTTG expression was not evidenced. As a tumor marker, hPTTG could be of special interest in categorizing subgroups of lympho- Figure 2 Northern blot analysis of hpttg mRNA expression in lymphoma tissue samples. Ten mg of total RNA from frozen tissue samples were electrophoresed in 1% agarose-formaldehyde gels, transferred onto nylon membranes, and hybridized to a 32 P-labeled full-length hpttg cDNA probe. Hybridizations to 18S probe are also shown as controls of RNA loading. Scanning densitometry was performed for quantitation using ScanAnalysis software (Biosoft, Cambridge, UK). FCL, follicle center cell lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone B-cell lymphoma; PCM, plasma cell myeloma; DLBL, diffuse large Bcell lymphoma; BL, Burkitt's lymphoma; TCL, peripheral T-cell lymphoma; HD, Hodgkin' disease; Hyp, hyperplastic lymph node; NLN, normal lymph node hpttg expression in lymphomas C Sáez et al mas with poor patient survival (peripheral T-cell lymphomas, diffuse large B-cell lymphomas) and future studies will help to determine the impact of hPTTG overexpression in the prognosis and treatment of lymphoma patients.
